362 related articles for article (PubMed ID: 26981507)
41. Recurrent malignant glioma in adults.
Tatter SB
Curr Treat Options Oncol; 2002 Dec; 3(6):509-24. PubMed ID: 12392640
[TBL] [Abstract][Full Text] [Related]
42. Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report.
Umphlett M; Shea S; Tome-Garcia J; Zhang Y; Hormigo A; Fowkes M; Tsankova NM; Yong RL
BMC Cancer; 2020 Jan; 20(1):47. PubMed ID: 31959133
[TBL] [Abstract][Full Text] [Related]
43. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
44. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
45. Glioblastoma multiforme: State of the art and future therapeutics.
Wilson TA; Karajannis MA; Harter DH
Surg Neurol Int; 2014; 5():64. PubMed ID: 24991467
[TBL] [Abstract][Full Text] [Related]
46. Large volume reirradiation as salvage therapy for glioblastoma after progression on bevacizumab.
Magnuson W; Ian Robins H; Mohindra P; Howard S
J Neurooncol; 2014 Mar; 117(1):133-9. PubMed ID: 24469853
[TBL] [Abstract][Full Text] [Related]
47. Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a TOP2A inhibitor.
Arivazhagan A; Kumar DM; Sagar V; Patric IR; Sridevi S; Thota B; Srividya MR; Prasanna K; Thennarasu K; Mondal N; Hegde AS; Chandramouli BA; Santosh V; Rao MR; Kondaiah P; Somasundaram K
J Neurooncol; 2012 Apr; 107(2):289-97. PubMed ID: 22102081
[TBL] [Abstract][Full Text] [Related]
48. Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.
Okonogi N; Shirai K; Oike T; Murata K; Noda SE; Suzuki Y; Nakano T
Anticancer Res; 2015 Mar; 35(3):1229-35. PubMed ID: 25750269
[TBL] [Abstract][Full Text] [Related]
49. The Current State of Potential Therapeutic Modalities for Glioblastoma Multiforme: A Clinical Review.
Mohtashami E; Shafaei-Bajestani N; Mollazadeh H; Mousavi SH; Jalili-Nik M; Sahebkar A; Afshari AR
Curr Drug Metab; 2020; 21(8):564-578. PubMed ID: 32664839
[TBL] [Abstract][Full Text] [Related]
50. Crosstalk between PI3K/AKT/mTOR and WNT/β-Catenin signaling in GBM - Could combination therapy checkmate the collusion?
Daisy Precilla S; Biswas I; Kuduvalli SS; Anitha TS
Cell Signal; 2022 Jul; 95():110350. PubMed ID: 35525406
[TBL] [Abstract][Full Text] [Related]
51. The evolving role of antiangiogenic therapies in glioblastoma multiforme: current clinical significance and future potential.
Anthony C; Mladkova-Suchy N; Adamson DC
Expert Opin Investig Drugs; 2019 Sep; 28(9):787-797. PubMed ID: 31356114
[No Abstract] [Full Text] [Related]
52. Xanthohumol regulates miR-4749-5p-inhibited RFC2 signaling in enhancing temozolomide cytotoxicity to glioblastoma.
Ho KH; Kuo TC; Lee YT; Chen PH; Shih CM; Cheng CH; Liu AJ; Lee CC; Chen KC
Life Sci; 2020 Aug; 254():117807. PubMed ID: 32422304
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma.
Barazzuol L; Jena R; Burnet NG; Meira LB; Jeynes JC; Kirkby KJ; Kirkby NF
Radiat Oncol; 2013 Mar; 8():65. PubMed ID: 23510353
[TBL] [Abstract][Full Text] [Related]
54. Current Perspectives on Therapies, Including Drug Delivery Systems, for Managing Glioblastoma Multiforme.
Bhaskaran M; Devegowda VG; Gupta VK; Shivachar A; Bhosale RR; Arunachalam M; Vaishnavi T
ACS Chem Neurosci; 2020 Oct; 11(19):2962-2977. PubMed ID: 32945654
[TBL] [Abstract][Full Text] [Related]
55. The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme.
Bambury RM; Morris PG
Expert Rev Anticancer Ther; 2014 Aug; 14(8):955-64. PubMed ID: 24814143
[TBL] [Abstract][Full Text] [Related]
56. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.
Raizer JJ
J Neurooncol; 2005 Aug; 74(1):77-86. PubMed ID: 16078112
[TBL] [Abstract][Full Text] [Related]
57. Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance.
Wu W; Klockow JL; Zhang M; Lafortune F; Chang E; Jin L; Wu Y; Daldrup-Link HE
Pharmacol Res; 2021 Sep; 171():105780. PubMed ID: 34302977
[TBL] [Abstract][Full Text] [Related]
58. A narrative review of research progress on drug therapies for glioblastoma multiforme.
Zheng X; Tang Q; Ren L; Liu J; Li W; Fu W; Wang J; Du G
Ann Transl Med; 2021 Jun; 9(11):943. PubMed ID: 34350258
[TBL] [Abstract][Full Text] [Related]
59. Quercetin induces MGMT
Wang W; Yuan X; Mu J; Zou Y; Xu L; Chen J; Zhu X; Li B; Zeng Z; Wu X; Yin Z; Wang Q
Phytomedicine; 2023 Sep; 118():154933. PubMed ID: 37451151
[TBL] [Abstract][Full Text] [Related]
60. Therapeutic strategies of recurrent glioblastoma and its molecular pathways 'Lock up the beast'.
El-Khayat SM; Arafat WO
Ecancermedicalscience; 2021; 15():1176. PubMed ID: 33680090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]